Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Evaluation of complement proteins as screening markers for colorectal cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. TERT promoter mutations in primary and secondary WHO grade III meningioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Ki-67 Proliferation Index as a Marker of Time to Recurrence in Intracranial Meningioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Preoperative antibiotic prophylaxis regimen in brain tumour surgery in Sweden: a quasi-experimental study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Return to work following diagnosis of low-grade glioma: A nationwide matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Human RTEL1 associates with Poldip3 to facilitate responses to replication stress and R-loop resolution

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Zhenjiang Liu
  • Thomas Poiret
  • Oscar Persson
  • Qingda Meng
  • Lalit Rane
  • Jiri Bartek
  • Julia Karbach
  • Hans-Michael Altmannsberger
  • Christopher Illies
  • Xiaohua Luo
  • Inti Harvey-Peredo
  • Elke Jäger
  • Ernest Dodoo
  • Markus Maeurer
View graph of relations

The prognosis for patients with glioblastoma is grim. Ex vivo expanded tumor-associated antigen (TAA)-reactive T-cells from patients with glioma may represent a viable source for anticancer-directed cellular therapies. Immunohistochemistry was used to test the survivin (n = 40 samples) and NY-ESO-1 (n = 38 samples) protein expression in tumor specimens. T-cells from peripheral blood were stimulated with TAAs (synthetic peptides) in IL-2 and IL-7, or using a combination of IL-2, IL-15 and IL-21. CD4+ and CD8+ T-cells were tested for antigen-specific proliferation by flow cytometry, and IFN-γ production was tested by ELISA. Twenty-eight out of 38 cancer specimens exhibited NY-ESO-1 protein expression, 2/38 showed a strong universal (4+) NY-ESO-1 staining, and 9/40 cancer lesions exhibited a strong (4+) staining for survivin. We could detect antigen-specific IFN-γ responses in 25% blood samples for NY-ESO-1 and 30% for survivin. NY-ESO-1-expanded T-cells recognized naturally processed and presented epitopes. NY-ESO-1 or survivin expression in glioma represents viable targets for anticancer-directed T-cells for the biological therapy of patients with glioma.

Original languageEnglish
JournalCancer immunology, immunotherapy
Volume67
Issue number2
Pages (from-to)237-246
ISSN0340-7004
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 52379439